Stay updated on PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.

Latest updates to the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe clinical trial page now displays the study record for glioblastoma/gliosarcoma, with details on its treatments, participant eligibility, measured outcomes, and study sites.SummaryDifference56%

- Check20 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error instead of study details.SummaryDifference0.2%

- Check27 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. The study page continues to display a 403 error.SummaryDifference1%

- Check34 days agoChange DetectedThe site footer revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check62 days agoChange DetectedThe study page now displays a 403 Forbidden error, indicating the record is currently inaccessible on ClinicalTrials.gov.SummaryDifference19%

Stay in the know with updates to PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.